Public subsidies for R&D and public sector pharmaceutical innovation

Dimitrios Kourouklis
Additional contact information
Dimitrios Kourouklis: CERNA i3 - Centre d'économie industrielle i3 - Mines Paris - PSL (École nationale supérieure des mines de Paris) - PSL - Université Paris Sciences et Lettres - I3 - Institut interdisciplinaire de l’innovation - CNRS - Centre National de la Recherche Scientifique, OHE - Office of Health Economics

Post-Print from HAL

Date: 2021-02-26
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Published in Applied Economics, 2021, pp.1-19. ⟨10.1080/00036846.2021.1885614⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-03154800

DOI: 10.1080/00036846.2021.1885614

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().